Jiao Beibei, Chen Ruilin, Chen Si, Zhang Jian, Wang Peijuan, Zhou Huaijun, Zhao Weibo
Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
Front Pharmacol. 2024 Aug 15;15:1458621. doi: 10.3389/fphar.2024.1458621. eCollection 2024.
Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder that affects women of reproductive age, characterized by chronic anovulation, hyperandrogenism, and polycystic ovarian morphology. Emerging evidence indicates that neurological disorders play a significant role in the etiology of PCOS, highlighting the complex interplay between the central nervous system (CNS) and ovarian function. Yulinzhu, a traditional Chinese medicine (TCM) formulation, has been traditionally used to regulate menstrual cycles and improve fertility. This study aims to investigate the efficacy and mechanisms of Yulinzhu in treating PCOS induced by neurological disorders.
An extensive literature search was performed across electronic databases such as PubMed, EMBASE, Cochrane Library, and China National Knowledge Infrastructure (CNKI), covering publications up to 1 June 2024. The review included randomized controlled trials (RCTs) that compared Yulin Zhu with placebo, standard care, or other active treatments in patients with PCOS. Two reviewers independently carried out data extraction and quality assessment. Meta-analyses were conducted using both fixed and random-effects models, with heterogeneity evaluated using the I statistic.
We screened 891 records and included 6 studi es in the meta-analysis. The meta-analysis revealed that Yulinzhu about effective rate [RR = 1.19, 95% CI (1.10, 1.29), < 0.0001], pregnancy rate [RR = 2.80, 95% CI (1.65, 4.76), < 0.0001] and ovulation rate [RR = 1.33, 95% CI (1.10, 1.62), = 0.04]. Meta-analysis shows the results of follicle estrogen [WMD = 0.69, 95% CI (-0.39, 1.78), = 0.21], luteinizing hormone [WMD = -2.27, 95% CI (-3.86, -0.67), = 0.005], testosterone [WMD = -0.44, 95% CI (-0.64, -0.25), < 0.0001], estradiol [WMD = 16.20, 95% CI (2.74, 29.67), < 0.0001].
This study demonstrates that plant medicine compund Yulinzhu may effectively treats PCOS including hormonal regulation, anti-inflammatory actions, and neuroprotection. We expect further research with larger, well-designed clinical trials to substantiate our conclusions.
多囊卵巢综合征(PCOS)是一种常见的内分泌紊乱疾病,影响育龄女性,其特征为慢性无排卵、高雄激素血症和多囊卵巢形态。新出现的证据表明,神经系统疾病在PCOS的病因中起重要作用,突显了中枢神经系统(CNS)与卵巢功能之间复杂的相互作用。毓麟珠,一种传统中药配方,一直被用于调节月经周期和提高生育能力。本研究旨在探讨毓麟珠治疗神经系统疾病诱发的PCOS的疗效及作用机制。
在PubMed、EMBASE、Cochrane图书馆和中国知网(CNKI)等电子数据库中进行了广泛的文献检索,涵盖截至2024年6月1日的出版物。该综述纳入了将毓麟珠与安慰剂、标准治疗或其他活性治疗方法相比较的多囊卵巢综合征患者的随机对照试验(RCT)。两名评审员独立进行数据提取和质量评估。采用固定效应模型和随机效应模型进行荟萃分析,使用I统计量评估异质性。
我们筛选了891条记录,纳入荟萃分析的有6项研究。荟萃分析显示,毓麟珠在有效率方面[RR = 1.19,95%CI(1.10,1.29),P < 0.0001]、妊娠率方面[RR = 2.80,95%CI(1.65,4.76),P < 0.0001]和排卵率方面[RR = 1.33,95%CI(1.10,1.62),P = 0.04]有显著效果。荟萃分析显示卵泡雌激素的结果为[WMD = 0.69,95%CI(-0.39,1.78),P = 0.21],促黄体生成素为[WMD = -2.27,95%CI(-3.86,-0.67),P = 0.005],睾酮为[WMD = -0.44,95%CI(-0.64,-0.25),P < 0.0001],雌二醇为[WMD = 16.20,95%CI(2.74,29.67),P < 0.0001]。
本研究表明,植物药复方毓麟珠可能有效治疗PCOS,包括激素调节、抗炎作用和神经保护作用。我们期待通过更大规模、设计良好的临床试验进行进一步研究,以证实我们的结论。